Please wait...


Generic Name: fosamprenavir (FOS am PREN a veer)
Brand Names: Lexiva
Lexiva is used to treat human immunodeficiency virus (HIV), which causes AIDS. Learn about side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Lexiva

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Lexiva (fosamprenavir) is an antiviral medicine that prevents human immunodeficiency virus (HIV) from multiplying in your body. Lexiva is used to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). Lexiva is for use in adults and children who are at least 4 weeks old. This medicine is not a cure for HIV or AIDS. Do not take Lexiva together with another HIV medicine called ritonavir if you are also using flecainide or propafenone to treat a heart rhythm disorder. Ask your doctor about taking a different heart rhythm medication during treatment with Lexiva. Learn more

Lexiva Side Effects

Lexiva Side Effects

Note: This document contains side effect information about fosamprenavir. Some of the dosage forms listed on this page may not apply to the brand name Lexiva.

In Summary

Common side effects of Lexiva include: skin rash. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to fosamprenavir: oral suspension, oral tablet

Along with its needed effects, fosamprenavir (the active ingredient contained in Lexiva) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking fosamprenavir:

More common

  • Severe skin rash

Less common

  • Abdominal or stomach pain
  • blurred vision
  • depression
  • dry mouth
  • flushed, dry skin
  • fruit-like breath odor
  • increased hunger
  • increased thirst
  • increased urination
  • mood or mental changes
  • nausea
  • sweating
  • troubled breathing
  • unexplained weight loss
  • unusual tiredness or weakness
  • vomiting


  • Back, leg, or stomach pains
  • bleeding gums
  • blistering, peeling, or loosening of the skin
  • chills
  • cough
  • dark urine
  • diarrhea
  • difficulty with breathing
  • fever
  • general body swelling
  • itching
  • joint or muscle pain
  • loss of appetite
  • nosebleeds
  • pale skin
  • red skin lesions often with a purple center
  • red, irritated eyes
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • yellowing of the eyes or skin

Incidence not known

  • Large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs

Some side effects of fosamprenavir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Mild or moderate rash

Less common

  • Burning or prickling sensation around the mouth
  • headache

Incidence not known

  • Breast enlargement
  • buffalo hump
  • increased fat deposits on the face, neck, and trunk
  • obesity

For Healthcare Professionals

Applies to fosamprenavir: oral suspension, oral tablet


Diarrhea, rash, nausea, vomiting, and headache were the most frequent moderate to severe side effects in clinical trials. Discontinuations due to side effects were 6.4% in patients using this drug compared to 5.9% in those using comparator therapies; the most common side effects leading to discontinuation of this drug (incidence up to 1%) included diarrhea, nausea, vomiting, increased AST, increased ALT, and rash.


Very common (10% or more): Skin rash (up to 19%)

Common (1% to 10%): Rash/cutaneous reactions (including erythematous or maculopapular cutaneous eruptions [with or without pruritus])

Rare (0.01% to 0.1%): Severe and/or life-threatening skin reactions (including Stevens-Johnson syndrome)

Frequency not reported: Erythema multiforme, pruritus

Postmarketing reports: Angioedema

Protease inhibitors:

-Frequency not reported: Lipohypertrophy

Skin rash (regardless of causality) was reported in about 19% of patients. Rashes were generally maculopapular and of mild or moderate intensity, some with pruritus. Rash had a median onset and duration of 11 and 13 days, respectively, and led to discontinuation of this drug in less than 1% of patients.


Very common (10% or more): Diarrhea (up to 13%)

Common (1% to 10%): Nausea, vomiting, abdominal pain, increased serum lipase, loose stools, gastritis, abdominal distension, upper abdominal pain, flatulence

Uncommon (0.1% to 1%): Gastroesophageal reflux disease

Frequency not reported: Increased amylase

Postmarketing reports: Oral paresthesia

Increased serum lipase (greater than 2 times the upper limit of normal [2 x ULN]) has been reported in up to 8% of patients.

Vomiting was reported more often in pediatric patients than adult patients.


Very common (10% or more): Increased fasting triglycerides (up to 11%)

Common (1% to 10%): Fatigue

Uncommon (0.1% to 1%): Pyrexia, increased cholesterol

Antiretroviral therapy:

-Frequency not reported: Increased weight, increased blood lipids

Increased fasting triglycerides (greater than 750 mg/dL) have been reported in up to 11% of patients.


Elevated ALT (greater than 5 x ULN) and AST (greater than 5 x ULN) have been reported in up to 8% and up to 6% of patients, respectively.

Common (1% to 10%): Elevated ALT, elevated AST

Frequency not reported: Liver toxicity


Common (1% to 10%): Decreased absolute neutrophil count, neutropenia


-Frequency not reported: Acute hemolytic anemia

Protease inhibitors:

-Frequency not reported: Spontaneous bleeding in patients with hemophilia A and B

Decreased absolute neutrophil count (less than 750 cells/mm3) has been reported in 3% of patients.

Neutropenia was reported more often in pediatric patients than adult patients.


Increased glucose (greater than 251 mg/dL) has been reported in 2% of patients.

Common (1% to 10%): Increased glucose, hyperlipidemia, hypertriglyceridemia

Uncommon (0.1% to 1%): Anorexia

Frequency not reported: Hyperglycemia, increased body fat

Postmarketing reports: Hypercholesterolemia

Protease inhibitors:

-Frequency not reported: Hypertriglyceridemia, hypercholesterolemia, resistance to insulin

-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, diabetic ketoacidosis

Antiretroviral therapy:

-Frequency not reported: Increased glucose

Nervous system

Common (1% to 10%): Headache, dizziness


Common (1% to 10%): Drug hypersensitivity


Postmarketing reports: Myocardial infarction


Postmarketing reports: Nephrolithiasis


Frequency not reported: Elevated creatine kinase, osteonecrosis

Protease inhibitors:

-Rare (0.01% to 0.1%): Rhabdomyolysis

-Frequency not reported: Increased creatine phosphokinase, myalgia, myositis


Frequency not reported: Depressive/mood disorders


Frequency not reported: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Lexiva